http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0057851-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6775cb403cec7f516c84ec5d4c2fc81a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2000-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e011d84a5f54f12f1b0724b96d200ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b8b1b28f7bbadc2c7a867112cd686d8
publicationDate 2001-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-0057851-A3
titleOfInvention High potency dihydroergotamine compositions
abstract The present invention is directed to improved formulations for dihydroergotamine in which the drug is present at a concentration of at least 2.9 mM. The invention encompasses methods for using these formulations in treating patients for migraine headaches and the packaging of formulation into prefilled syringes for self-administration by patients.
priorityDate 1999-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BE-881967-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-2555481-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0074620-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9625190-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152743199
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503510
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226429103
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10531
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226429104
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6426689

Total number of triples: 39.